Roya Raeisi Jaski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roya Raeisi Jaski has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Nasim Zaman Samghabadi
Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications - Ahmad Maleki Ahmadabadi
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication - Alireza Habibzadeh
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication - Babak Gholamine
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Banafsheh Tehranineshat
Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication - Faezeh Khajeh
Department of Anesthesiology, School of Paramedical Sciences, Gonabad University of Medical Sciences, Gonabad, Iran
1 shared publication
Latest Publications
- 28 March 2026
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12, e44029
From hyperandrogenism to tumorigenesis; a mechanistic perspective on cancer development in PCOS-affected women
The mechanistic sequence from hyperandrogenism to tumorigenesis in women with polycystic ovary syndrome (PCOS) encompasses a constellation of structural and functional aberrations spanning the endocrine, metabolic, immunologic, and genetic domains. Chronic hyperandrogenism incites an interconnected cascade through chronic anovulation and unopposed estrogen action, insulin resistance with hyperinsulinemia, low-grade systemic inflammation, oxidative stress, and gut dysbiosis, each playing a synergistic role in promoting oncogenesis. It has been demonstrated that, this syndrome is most strongly associated with an increased risk of endometrial cancer, with a more modest and less consistent association with ovarian and breast cancers. Thyroid cancer risk may also be elevated, particularly in younger women. The underlying mechanisms involve hormonal imbalances, metabolic dysfunction, chronic inflammation, and genetic predisposition. Women with PCOS should be monitored for early signs of these cancers, and management should focus on mitigating risk factors such as obesity, insulin resistance, and chronic anovulation.
- 28 March 2026
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12, e44029
From hyperandrogenism to tumorigenesis; a mechanistic perspective on cancer development in PCOS-affected women
The mechanistic sequence from hyperandrogenism to tumorigenesis in women with polycystic ovary syndrome (PCOS) encompasses a constellation of structural and functional aberrations spanning the endocrine, metabolic, immunologic, and genetic domains. Chronic hyperandrogenism incites an interconnected cascade through chronic anovulation and unopposed estrogen action, insulin resistance with hyperinsulinemia, low-grade systemic inflammation, oxidative stress, and gut dysbiosis, each playing a synergistic role in promoting oncogenesis. It has been demonstrated that, this syndrome is most strongly associated with an increased risk of endometrial cancer, with a more modest and less consistent association with ovarian and breast cancers. Thyroid cancer risk may also be elevated, particularly in younger women. The underlying mechanisms involve hormonal imbalances, metabolic dysfunction, chronic inflammation, and genetic predisposition. Women with PCOS should be monitored for early signs of these cancers, and management should focus on mitigating risk factors such as obesity, insulin resistance, and chronic anovulation.
- Open Access
- 4 April 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
Prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital
Introduction: Surgery cancellation causes complications such as disrupting the daily schedule of surgery in the operating room, delays in patient care, and potential financial losses for the hospital or surgical center. Objectives: This study aimed to investigate the prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital. Patients and Methods: This descriptive-analytical study was conducted on 212 patients in the Shariati hospital of Bandar Abbas, Iran, from April to November 2023. Data were collected through a demographic questionnaire and a researcher-made checklist, including clinical data. To analyze data SPSS version 27 and analytical tests were used. Results: Out of 212 studied patients, the surgery for 67 was canceled, resulting in a surgery canceling prevalence rate of 31.6%. Surgery type, age, history of diabetes mellitus, thyroid disease, and other diseases were not risk factors for surgery cancelation (P>0.05); however, cardiovascular disease history, not being nil per os (NPO), and not having surgery consent were independent risk factors (P<0.05). Conclusion: In conclusion, the high prevalence of surgery cancellations in Iran’s educational hospitals necessitates a comprehensive and systematic investigation of the factors involved, including patient evaluation, anesthesiologist approval, patient readiness, and the impact on patients’ overall health and well-being.
- 4 April 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
Open AccessPrevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital
Introduction: Surgery cancellation causes complications such as disrupting the daily schedule of surgery in the operating room, delays in patient care, and potential financial losses for the hospital or surgical center. Objectives: This study aimed to investigate the prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital. Patients and Methods: This descriptive-analytical study was conducted on 212 patients in the Shariati hospital of Bandar Abbas, Iran, from April to November 2023. Data were collected through a demographic questionnaire and a researcher-made checklist, including clinical data. To analyze data SPSS version 27 and analytical tests were used. Results: Out of 212 studied patients, the surgery for 67 was canceled, resulting in a surgery canceling prevalence rate of 31.6%. Surgery type, age, history of diabetes mellitus, thyroid disease, and other diseases were not risk factors for surgery cancelation (P>0.05); however, cardiovascular disease history, not being nil per os (NPO), and not having surgery consent were independent risk factors (P<0.05). Conclusion: In conclusion, the high prevalence of surgery cancellations in Iran’s educational hospitals necessitates a comprehensive and systematic investigation of the factors involved, including patient evaluation, anesthesiologist approval, patient readiness, and the impact on patients’ overall health and well-being.
- Open Access
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Open AccessInvestigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites